Breakthrough Therapies: Another Drug’s Approval Should Not Lead To De Facto Rescission, Industry Says
Executive Summary
Industry and patient advocacy groups urge the agency to consider a variety of factors in determining whether a drug’s breakthrough designation should be rescinded upon the approval of another product; draft guidance language on quality of clinical evidence to be considered in rescission decisions raises concerns specific to rare disease populations.
You may also be interested in...
Breakthrough Therapies: Failed Study Won’t Automatically Lead To Rescinded Designation
The decision to maintain or revoke breakthrough therapy status when trial results do not appear to support the original designation will depend on the facts specific to a development program, the US FDA says in new draft guidance. Since 2012, the agency has granted 475 breakthrough therapy designation requests and rescinded 35 designations.
How FDA Will Take Away A ‘Breakthrough’ Designation
Process for rescinding designation under the expedited regulatory pathway will begin with an internal FDA multidisciplinary meeting and review division director agreement on an intent-to-rescind decision.
Rare Diseases: CBER Looks To ‘Lean Into’ Accelerated Approval, Align More With CDER
US FDA biologics center officials spoke about their efforts to increase collaboration and harmonization with the drugs center, and to internally involve more review disciplines in evaluating biomarker evidence, during a Reagan-Udall Foundation meeting that weighed potential use of accelerated approval for neuronopathic mucopolysaccharidoses disorders.